×
About 7,710 results

ALLMedicine™ Gastrointestinal Stromal Tumors Center

Research & Reviews  3,669 results

Progressive cerebellar atrophy in a patient with complex II and III deficiency and a no...
https://doi.org/10.1002/mgg3.1692
Molecular Genetics & Genomic Medicine; Sturrock BRH, Macnamara EF et. al.

May 7th, 2021 - Complex II is an essential component of the electron transport chain, linking it with the tricarboxylic acid cycle. Its four subunits are encoded in the nuclear genome, and deleterious variants in these genes, including SDHA (OMIM 600857), are ass...

Ripretinib and MEK inhibitors synergize to induce apoptosis in preclinical models of GI...
https://doi.org/10.1158/1535-7163.MCT-20-0824
Molecular Cancer Therapeutics; Gupta A, Singh J et. al.

May 5th, 2021 - The majority of gastrointestinal stromal tumors (GIST) harbor constitutively activating mutations in KIT tyrosine kinase. Imatinib, sunitinib, and regorafenib are available as first, second, and third-line targeted therapies, respectively, for met...

Reversing Imatinib's Immunosuppressive Effects by Modulating Type I IFN Signaling.
https://doi.org/10.1158/2326-6066.CIR-21-0177
Cancer Immunology Research; Largaespada DA

May 4th, 2021 - Signal pathway inhibition is a well-validated approach for treating cancers driven by activated kinases such as KIT. However, kinase inhibitors may make tumor cells less responsive to tumor immune surveillance and less sensitive to immunotherapies...

Characteristics of Gastrointestinal Stromal Tumors incidentally discovered during abdom...
https://doi.org/10.1016/j.amjsurg.2021.04.010
American Journal of Surgery; Hitscherich KJ, Garg M et. al.

May 2nd, 2021 - Gastrointestinal Stromal Tumors (GISTs) are rare sarcomas with 5000 new cases arising in the United States each year. Despite their low incidence, general surgeons should be familiar with GISTs since a quarter of these neoplasms are encountered in...

see more →

Guidelines  11 results

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Three Years of Imatinib Improves OS in High-Risk Operable GIST
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/

May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/...

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295840
World Journal of Gastroenterology; Li J, Wang M et. al.

Dec 25th, 2018 - Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or conse...

Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, t...
https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy095/5004450
Casali, P. G.

May 27th, 2018 - Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/year. This only covers clinically relevant GISTs, since, if investigated, a much higher number of lesions ≤ 1 cm in diameter (mic.

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal str...
https://doi.org/10.1093/annonc/mdu360
Annals of Oncology : Official Journal of the European Soc... Bellera CA, Penel N et. al.

Jul 29th, 2014 - The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-even...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  3,863 results

Progressive cerebellar atrophy in a patient with complex II and III deficiency and a no...
https://doi.org/10.1002/mgg3.1692
Molecular Genetics & Genomic Medicine; Sturrock BRH, Macnamara EF et. al.

May 7th, 2021 - Complex II is an essential component of the electron transport chain, linking it with the tricarboxylic acid cycle. Its four subunits are encoded in the nuclear genome, and deleterious variants in these genes, including SDHA (OMIM 600857), are ass...

Ripretinib and MEK inhibitors synergize to induce apoptosis in preclinical models of GI...
https://doi.org/10.1158/1535-7163.MCT-20-0824
Molecular Cancer Therapeutics; Gupta A, Singh J et. al.

May 5th, 2021 - The majority of gastrointestinal stromal tumors (GIST) harbor constitutively activating mutations in KIT tyrosine kinase. Imatinib, sunitinib, and regorafenib are available as first, second, and third-line targeted therapies, respectively, for met...

Reversing Imatinib's Immunosuppressive Effects by Modulating Type I IFN Signaling.
https://doi.org/10.1158/2326-6066.CIR-21-0177
Cancer Immunology Research; Largaespada DA

May 4th, 2021 - Signal pathway inhibition is a well-validated approach for treating cancers driven by activated kinases such as KIT. However, kinase inhibitors may make tumor cells less responsive to tumor immune surveillance and less sensitive to immunotherapies...

Characteristics of Gastrointestinal Stromal Tumors incidentally discovered during abdom...
https://doi.org/10.1016/j.amjsurg.2021.04.010
American Journal of Surgery; Hitscherich KJ, Garg M et. al.

May 2nd, 2021 - Gastrointestinal Stromal Tumors (GISTs) are rare sarcomas with 5000 new cases arising in the United States each year. Despite their low incidence, general surgeons should be familiar with GISTs since a quarter of these neoplasms are encountered in...

see more →

News  161 results

EMA Green Light for Avapritinib for GIST, Acalabrutinib for CLL
https://www.staging.medscape.com/viewarticle/934648

Jul 26th, 2020 - The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a thumbs up to two new oncology drugs.  The Committee has recommended granting conditional marketing authorization for avapritinib (Ayvakit, Bluepr...

EMA Green Light for Avapritinib for GIST, Acalabrutinib for CLL
https://www.medscape.com/viewarticle/934648

Jul 26th, 2020 - The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a thumbs up to two new oncology drugs.  The Committee has recommended granting conditional marketing authorization for avapritinib (Ayvakit, Bluepr...

Ripretinib Extends Survival When All Else Fails in Advanced GIST
https://www.medscape.com/viewarticle/933412

Jul 5th, 2020 - NEW YORK (Reuters Health) - Treatment with oral ripretinib significantly prolonged survival in patients with advanced gastrointestinal stromal tumors (GIST) who did not respond or were intolerant to three other tyrosine-kinase inhibitors in the IN...

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Three Years of Imatinib Improves OS in High-Risk Operable GIST
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/

May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/...

see more →

Patient Education  4 results see all →